Rabbit as an animal model to predict CYP3A-mediated drug-drug interactions

被引：0
|
作者：
Chauret, N [1 ]
Sleno, L [1 ]
Silva, J [1 ]
Houle, R [1 ]
Day, S [1 ]
Nicoll-Griffith, DA [1 ]
机构：
[1] Merck Frosst Ctr Therapeut Res, Pointe Claire, PQ H9R 4P8, Canada
来源：
CYTOCHROMES P450, BIOCHEMISTRY, BIOPHYSICS AND DRUG METABOLISM | 2003年
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：157 / 162
页数：6
相关论文
共 50 条
  • [1] Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions
    Khalilieh, Sauzanne G.
    Yee, Ka Lai
    Sanchez, Rosa I.
    Fan, Li
    Anderson, Matt S.
    Sura, Monali
    Laethem, Tine
    Rasmussen, Scott
    van Bortel, Luc
    van Lancker, Griet
    Iwamoto, Marian
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (05)
  • [2] A simplified approach to predict CYP3A-mediated drug-drug interactions at early drug discovery: validation with clinical data
    Rioux, Nathalie
    Batonga, Joelle
    Colombo, Federico
    Masse, Jonathan
    Zouki, Christine
    Ribadeneira, Maria D.
    Duan, Jianmin
    Bethell, Richard C.
    XENOBIOTICA, 2013, 43 (07) : 592 - 597
  • [3] Evaluation of CYP3A-Mediated Drug-Drug Interactions With Romidepsin in Patients With Advanced Cancer
    Laille, Eric
    Patel, Manish
    Jones, Suzanne F.
    Burris, Howard A., III
    Infante, Jeffrey
    Lemech, Charlotte
    Liu, Liangang
    Arkenau, Hendrik-Tobias
    JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (12): : 1378 - 1385
  • [4] Proposal of a Safe and Effective Study Design for CYP3A-Mediated Drug-Drug Interactions
    Rohr, Brit Silja
    Mikus, Gerd
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (10): : 1294 - 1303
  • [5] Model-based assessments of CYP3A-mediated drug-drug interaction risk of milademetan
    Hong, Ying
    Ishizuka, Tomoko
    Watanabe, Akiko
    Tachibana, Masaya
    Lee, Mark
    Ishizuka, Hitoshi
    LaCreta, Frank
    Abutarif, Malaz
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (06): : 2220 - 2230
  • [6] Prediction of CYP3A-Mediated Drug-Drug Interactions Using Human Hepatocytes Suspended in Human Plasma
    Mao, Jialin
    Mohutsky, Michael A.
    Harrelson, John P.
    Wrighton, Steven A.
    Hall, Stephen D.
    DRUG METABOLISM AND DISPOSITION, 2011, 39 (04) : 591 - 602
  • [7] IMPACT OF CYP3A5 EXPRESSION ON THE INHIBITION OF CYP3A-CATALYZED DRUG METABOLISM: CONSIDERATIONS FOR MODELING CYP3A-MEDIATED DRUG-DRUG INTERACTIONS
    Shirasaka, Yoshiyuki
    Peng, Chi-Chi
    Chang, Shu-Ying
    Grubb, Mary F.
    Johnson, Stephen R.
    Rodrigues, A. David
    Thummel, Kenneth E.
    Isoherranen, Nina
    DRUG METABOLISM REVIEWS, 2012, 44 : 83 - 84
  • [8] Effect of CYP3A5 Expression on the Inhibition of CYP3A-Catalyzed Drug Metabolism: Impact on Modeling CYP3A-Mediated Drug-Drug Interactions
    Shirasaka, Yoshiyuki
    Chang, Shu-Ying
    Grubb, Mary F.
    Peng, Chi-Chi
    Thummel, Kenneth E.
    Isoherranen, Nina
    Rodrigues, A. David
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (08) : 1566 - 1574
  • [9] Quantitative prediction of CYP3A-mediated drug interactions.
    Kimura, RE
    Chen, YC
    Jiyamapa-Sherna, VA
    Hamman, MA
    Hall, SD
    Galinsky, RE
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P16 - P16
  • [10] Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model
    Rioux, Nathalie
    Bellavance, Edith
    Bourg, Serge
    Garneau, Michel
    Ribadeneira, Maria D.
    Duan, Jianmin
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2013, 34 (07) : 396 - 401
12345